On behalf of the Cancer Research Institute (CRI), I thank you for joining us at the 2017 Immunotherapy Patient Summit. CRI is proud to be the world’s leading nonprofit organization dedicated exclusively to harnessing the immune system’s power to cure all cancers.

This important work has led to a promising new class of cancer treatments called cancer immunotherapy. These treatments can mobilize, strengthen, and sustain the immune system’s ability to find and destroy cancer cells, wherever they are in the body.

CRI awards grants and fellowships to support scientists at leading research universities and clinics throughout the world. Our funding decisions are guided by a Scientific Advisory Council composed of renowned immunologists and tumor immunologists, including Nobel Prize winners and members of the National Academy of Sciences. CRI also offers educational programming on cancer immunotherapy for patients, caregivers, and healthcare professionals.

Immunotherapy has reached a tipping point and the involvement of patients, caregivers, and advocates is critical to helping ensure cancer patients of all types have access to these important new treatments. I look forward to a day of learning, networking, and sharing with all of you.
9:00am
Registration and networking

10:00am
Program commences

Welcome
Jill O’Donnell-Tormey, Ph.D.

Hear from the experts
Learn the basics of immunotherapy
Lewis Lanier, Ph.D.

Latest research update panel
Moderator
Lewis Lanier, Ph.D.

Panelists
Aaron Miller, M.D., Ph.D.
Stanley Riddell, M.D.
Ezra Cohen, M.D.

Patient perspective
Hear from a melanoma survivor
Janie Ferling

12:00pm
Lunch and Networking

1:00pm
Demystifying clinical trials
Learn about clinical trials and panel discussion
Moderator
Brian Brewer
Panelists
Johanna Packard
Philip Prichard
Janie Ferling

Breakout sessions
Your choice of moderated discussion with our experts or a general networking session

Blood Cancers
Stanley Riddell, M.D.

Colorectal Cancer
Aaron Miller, M.D., Ph.D.

Head and Neck Cancer
Ezra Cohen, M.D.

General Networking
Jill O’Donnell-Tormey, Ph.D.

3:15pm
Program closes

9:00am – 4:00pm
Clinical trial navigator appointments

Appointments will be available all day. If you didn’t pre-register, check with the registration desk.
Brian Brewer
Mr. Brewer is director of marketing and communications at the Cancer Research Institute. In this role he helps the organization shape and promote its mission, always with an eye on the patient who will ultimately benefit from immunotherapy. Prior to this role, he was the grants program administrator and has served in a variety of capacities at CRI for over 18 years. Brian holds a Master of Public Administration from NYU’s Robert F. Wagner Graduate School of Public Service.

Ezra Cohen, M.D.
Dr. Cohen is the associate director of translational science, a professor of medicine, and team leader in Head and Neck Oncology as well as the Solid Tumor Therapeutics research program at Moores Cancer Center at UC San Diego Health. Dr. Cohen is an internationally renowned translational researcher and physician-scientist who has been the principal investigator on multiple clinical trials of novel agents in head and neck cancer. He was recently appointed as chair of the NCI Head and Neck Cancer Steering Committee that oversees NCI-funded clinical research (including all NCI Cooperative Group trials) in this disease.

and also serves as a member of the Cancer Council, C3 steering committee, and the Moores Cancer Center’s Executive Committee.

Janie Ferling
Ms. Ferling was diagnosed with stage 3 metastatic melanoma in 2013. At the time, Janie’s son was in high school and she was busy running her own business. Following surgery and interferon treatments, new tumors began to grow. The only treatments available for Janie to try were traditional chemotherapy drugs that were described to her as very toxic and not effective. Janie refused to quit. She began looking for a clinical trial and enrolled in a study testing a new treatment that combined two immunotherapies—infusions of the checkpoint inhibitor pembrolizumab (Keytruda®), and injections of a deactivated herpes virus called T-Vac (Imlygic®), both of which have since received FDA approval as single-agent therapies in melanoma. After six months of treatment her tumors began to disappear. Today those tumors are gone and she just had her last infusion earlier this year. She will still need follow-up to ensure no recurrences but today Janie is living her life making more memories with her son.

Lewis Lanier, Ph.D.
Dr. Lanier is the chair of the Department of Microbiology and Immunology and the leader of the Cancer, Immunity, and Microenvironment Program at the University of California, San Francisco (UCSF) Comprehensive Cancer Center. Dr. Lanier is an expert on natural killer (NK) cells, and is renowned for his contributions to the characterization of how NK cells recognize and deal with virus-infected tissues. He’s identified many of the receptors that activate and inhibit NK cells, and has shown how they can be activated against cancer cells. For his contributions, he received the 2002 William B. Coley Award from the Cancer Research Institute, and earned membership in the National Academy of Sciences. He continues to explore the mechanisms that enable NK cells to distinguish between healthy cells and infected or cancerous cells.

Jill O’Donnell-Tormey, Ph.D.
Dr. O’Donnell-Tormey is chief executive officer and director of scientific affairs of the Cancer Research Institute. She joined the organization in 1987, and has been chief executive since 1993. Prior to joining CRI, she served as a research associate in the department of medicine at Cornell University Medical College and as a postdoctoral fellow in the laboratory of cellular physiology and immunology at The Rockefeller University. Dr. O’Donnell-Tormey serves on the Boards of SFG-Science Foundation for Oncology, Zurich, Switzerland; The City University of New York (CUNY), Richmond University Medical Center; and the Staten Island Foundation.

Aaron Miller, M.D., Ph.D.
Dr. Miller is an assistant professor in the Department of Medicine, holds a joint faculty appointment at the La Jolla Institute for Allergy and Immunology, and is actively involved in cancer research, with the aim of translating his discoveries in the lab into new ways of treating patients. Dr. Miller is part of the gastrointestinal cancer unit at UC San Diego Health’s Moores Cancer Center, where he uses chemotherapy, biological therapy, immunotherapy, and targeted therapy to

offer the best possible treatment options for his patients. His research focuses on tumor neoantigen identification as targets for novel immunotherapeutics that are both effective and avoid off-tumor toxicities. He and his colleagues have also created a new patient-derived xenograft platform that allows for preclinical testing of investigational chemotherapeutics and immune therapies.

Johanna Packard
Mrs. Packard’s husband, Andy, was first diagnosed with advanced prostate cancer in late 2014. His diagnosis came after a year and a half of discomfort and medical follow-up. When they learned of Andy’s
diagnosis, Johanna knew it was bad and immediately began researching all the options available. Johanna learned she couldn’t take no for an answer. After seeking multiple opinions, her research led them to a new medical team that offered them the most treatment options, resulting in Andy participating in an immunotherapy clinical trial of ipilimumab (Yervoy®). Andy participated in the clinical trial in 2015, following chemotherapy and surgery. After the trial, Andy went over a year with no treatment, which they consider a huge success. Andy credits Johanna for helping him find the best options available at a time when he felt overwhelmed. While Andy has had some progression of his PSA, he feels good, remains active, and he and Johanna remain busy with their teenage son, careers, and life in Berkeley, CA.

Philip Prichard

Mr. Prichard was first diagnosed in 2012 with kidney cancer and was shocked to learn he had a 3.8 pound tumor on his right kidney. The tumor was successfully removed but several months later the cancer returned and spread to his lungs and liver. Not satisfied with the chemotherapy options presented to them, Philip and his wife Susan sought out other options. Their research led them to a clinical trial for the immunotherapy nivolumab (Opdivo®). By the third month of the trial, his main tumor had shrunk by about 30 percent and by the spring of 2016, his tumors were virtually undetectable. Today, Philip is healthy

running his own business with his wife, and wants other patients to remain hopeful.

Stanley Riddell, M.D.

Dr. Riddell is a full member of the Program in Immunology of the Clinical Research Division at the Fred Hutchison Cancer Research Center, and a professor of Oncology at the University of Washington. Dr. Riddell is an expert in cell transplantations and T cell-based immunotherapies, and has used them to treat many patients with lymphoma and leukemia. He's contributed many advances that are widely used in cell-based immunotherapy approaches, including CAR T cells, and also led the first clinical trial that utilized adoptively transferred T cells. He has been elected to the Association of American Physicians, and his current work builds on his previous accomplishments and seeks to identify further ways to improve the effectiveness of T cell immunotherapies.
This event is made possible with generous support from the following sponsors:

- Bristol-Myers Squibb
- MERCK
- gsk
- AstraZeneca
- Genentech
- REGENERON
The Immunotherapy Patient Summit series will also be held in the following cities:

- **CHICAGO**  
  August 5

- **NEW YORK**  
  September 23

- **HOUSTON**  
  October 21

- **TAMPA**  
  December 9

CANCERRESEARCH.ORG/SUMMIT

CANCER RESEARCH INSTITUTE